Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. Part B (E-Book, 2019) [WorldCat.org]
zum Inhalt wechseln
Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. Part B Titelvorschau
SchließenTitelvorschau
Wird geprüft…

Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. Part B

Autor: Lijuan Zhang
Verlag: Cambridge : Academic Press, 2019.
Serien: Progress in molecular biology and translational science, v. 163.
Ausgabe/Medienart   E-Book : Dokument : EnglischAlle Ausgaben und Medienarten anzeigen
Zusammenfassung:
Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for  Weiterlesen…
Bewertung:

(noch nicht bewertet) 0 mit Rezensionen - Verfassen Sie als Erster eine Rezension.

Themen
Ähnliche Titel

Online-Exemplar suchen

Exemplar ausleihen

&AllPage.SpinnerRetrieving; Suche nach Bibliotheken, die diesen Titel besitzen ...

Details

Gattung/Form: Electronic books
Physisches Format Print version:
(OCoLC)1052874139
Medienart: Dokument, Internetquelle
Dokumenttyp Internet-Ressource, Computerdatei
Alle Autoren: Lijuan Zhang
ISBN: 9780128177396 012817739X 9780128177419 0128177411
OCLC-Nummer: 1090925584
Anmerkungen: Includes index.
Beschreibung: 1 online resource
Inhalt: Front Cover; Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics --
Part B; Copyright; Contents; Contributors; Preface; Chapter One: Heparin: An essential drug for modern medicine; 1. Introduction; 2. Structure of heparin; 3. The mechanisms of the heparin; 4. Clinical studies of heparin; 4.1. Anti-coagulation activity of heparin; 4.2. Anti-cancer activity of heparin; 4.3. Heparin in inflammatory diseases; 4.4. Heparin in infectious disease; 4.5. Other diseases; 5. Concluding remarks; Acknowledgments; References Chapter Two: Low molecular weight heparins and their clinical applications1. Introduction; 2. Structure of LMWHs; 3. Clinical uses of LMWHs; 4. Update on the LMWHs under clinic trials and its potential applications; 4.1. Anti-tumor; 4.2. Anti-viral; 4.3. Anti-inflammation; 4.4. Anti-diabetes-associated complications; 4.5. Other applications; 5. Concluding remarks; Acknowledgments; References; Chapter Three: The clinical use of Fondaparinux: A synthetic heparin pentasaccharide; 1. Structure and mechanism of Fondaparinux; 2. Pharmacokinetics and pharmacodynamics of Fondaparinux 3. Clinical application of Fondaparinux3.1. Prophylaxis of VTE; 3.2. Prophylaxis of DVT; 3.3. Other clinical indications; 4. Concluding remarks; Acknowledgments; Conflict of interest; References; Chapter Four: Heparinoids Danaparoid and Sulodexide as clinically used drugs; 1. Heparin and heparinoids; 2. Heparin, low molecular weight heparin, Danaparoid and Sulodexide; 3. Clinical applications of Danaparoid; 3.1. Danaparoid in HIT; 3.2. Danaparoid in DVT; 3.3. Danaparoid in DIC; 4. Clinical applications of Sulodexide; 4.1. Anticoagulant and antithrombotic activity 4.2. Prevention of reperfusion injury4.3. Sulodexide in other diseases; 5. Concluding remarks; Acknowledgments; References; Chapter Five: Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 31 years clinical exp ... ; 1. Introduction; 2. Preparation, chemical structure, and clinical doses; 3. Clinical uses and efficacy; 4. Adverse reactions; 5. Pharmacodynamics; 6. Pharmacokinetics; 7. Future perspectives; Acknowledgment; Conflicts of interest; References; Chapter Six: Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies 1. Introduction2. Preparation and structure of fucoidan; 3. Pharmacology and mechanism of fucoidan; 3.1. Chronic renal failure (CRF); 3.2. Acute kidney injury (AKI); 3.3. Diabetic nephropathy (DN); 4. Clinical uses and efficacy of fucoidan; 5. Future perspectives; Acknowledgments; References; Chapter Seven: Marine glycan-derived therapeutics in China; 1. Introduction; 2. Fucoidan (Haikunshenxi capsules); 2.1. Chemical structure and preparation; 2.2. Pharmacological activities; 2.3. Clinical applications; 3. Chitin ester (PS916); 3.1. Pharmacological activities; 3.2. Pharmacokinetics
Serientitel: Progress in molecular biology and translational science, v. 163.
Verfasserangabe: edited by Lijuan Zhang.

Abstract:

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases-30 Years Clinical Applications in China, and more.

Rezensionen

Nutzer-Rezensionen
Suche nach GoodReads-Rezensionen
Suche nach DOGObooks-Rezensionen…

Schlagwörter

Tragen Sie als Erster Schlagwörter ein.
Anfrage bestätigen

Sie haben diesen Titel bereits angefordert. Wenn Sie trotzdem fortfahren möchten, klicken Sie auf OK.

Fenster schließen

Bitte in WorldCat einloggen 

Sie haben kein Konto? Sie können sehr einfach ein kostenloses Konto anlegen,.